Journal of Cystic FibrosisMolecular BiologyPeer-reviewed journal article
TLN468 changes the pattern of tRNA used to readthrough premature termination codons in CFTR
Sabrina KarriiD, David CornuiD, Claudia SerotiD, Lynda Biri, Aurélie HattoniD, Elise Dréanot, Camille Rullaud, Iwona Maria PrankeiD, Isabelle Sermet‐GaudelusiD, Alexandre HinzpeteriD, Laure BidouiD, Olivier NamyiD
Abstract
Nonsense mutations account for 12% of cystic fibrosis (CF) cases. The presence of a premature termination codon (PTC) leads to gene inactivation, which can be countered by the use of drugs stimulating PTC readthrough, restoring production of the full-length protein. We recently identified a new readthrough inducer, TLN468, more efficient than gentamicin. We measured the readthrough induced by these two drugs with different cystic fibrosis transmembrane conductance regulator (CFTR) PTCs. We then determined the amino acids inserted at the S1196X, G542X, W846X and E1417X PTCs of CFTR during readthrough induced by gentamicin or TLN468. TLN468 significantly promoted the incorporation of one specific amino acid, whereas gentamicin did not greatly modify the proportions of the various amino acids incorporated relative to basal conditions. The function of the engineered missense CFTR channels corresponding to these four PTCs was assessed with and without potentiator. For the recoded CFTR, except for E1417Q and G542W, the PTC readthrough induced by TLN468 allowed the expression of CFTR variants that were correctly processed and had significant activity that was enhanced by CFTR modulators. These results suggest that it would be relevant to assess the therapeutic benefit of TLN468 PTC suppression in combination with CFTR modulators in preclinical assays.
- Citations
- 8
- FWCI
- 2.31
- Field percentile
- top 11%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Engineered tRNA suppression of a CFTR nonsense mutation
John D. Lueck, Daniel T. Infield, … Christopher A. Ahern·bioRxiv·Nov 20, 2016
- Anticodon Engineered Transfer RNAs (ACE-tRNAs) are a Platform Technology for Suppressing Nonsense Mutations
Wooree Ko, Joseph J. Porter, … John D. Lueck·bioRxiv·Jun 6, 2024
- Efficient Suppression of Endogenous CFTR Nonsense Mutations Using Anticodon Engineered Transfer RNAs
Wooree Ko, Joseph J. Porter, … John D. Lueck·Molecular Therapy — Nucleic AcidsPeer-reviewed·May 4, 2022
- Upregulation of a nonsense mediated decay (NMD) insensitive CFTR mRNA isoform has therapeutic potential for the treatment of 3 Prime CFTR PTC variants
Norm Allaire, M. Armstrong, … Calvin U. Cotton·bioRxiv·Jul 1, 2024
- 2-Guanidino-quinazoline promotes the readthrough of nonsense mutations underlying human genetic diseases
Laure Bidou, Olivier Bugaud, … Olivier Namy·bioRxiv·Nov 9, 2021
- Open reading frame correction using antisense oligonucleotides for the treatment of cystic fibrosis caused by CFTR-W1282X
W. E. Michaels, C. Pena-Rasgado, … M. L. Hastings·bioRxiv·Aug 11, 2021